Fund Details
PH
Piper Heartland Healthcare Capital
800 Nicollet Mall, Minneapolis, Minnesota, 55402, United States
Overview
Investment portfolio
18rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
AdvanCell | Jul 2026Participated | $315 MSeries D | |
Artios Pharma | Nov 2025Participated | $115 MSeries D | |
Kardium | Jul 2025Led | $248 MOther Equity | |
Saluda Medical | Jan 2025Participated | $100 MOther Equity | |
Alentis Therapeutics | Nov 2024Participated | $181 MSeries D | |
Endeavor BioMedicines | Apr 2024Participated | $133 MSeries C | |
Alumis | Mar 2024Participated | $259 MSeries C | |
ProfoundBio | Feb 2024Participated | $112 MSeries B | |
Boundless Bio | May 2023Participated | $100 MSeries C | |
Bicara Therapeutics | Mar 2023Participated | $108 MSeries B | |
CARGO Therapeutics | Mar 2023Participated | $200 MSeries A | |
Structure Therapeutics | Aug 2022Led | $33 MSeries B | |
AdvanCell | Jul 2026Participated | $315 MSeries D | |
Artios Pharma | Nov 2025Participated | $115 MSeries D | |
Kardium | Jul 2025Led | $248 MOther Equity | |
Saluda Medical | Jan 2025Participated | $100 MOther Equity | |
Alentis Therapeutics | Nov 2024Participated | $181 MSeries D | |
Endeavor BioMedicines | Apr 2024Participated | $133 MSeries C | |
Alumis | Mar 2024Participated | $259 MSeries C | |
ProfoundBio | Feb 2024Participated | $112 MSeries B | |
Boundless Bio | May 2023Participated | $100 MSeries C | |
Bicara Therapeutics | Mar 2023Participated | $108 MSeries B | |
CARGO Therapeutics | Mar 2023Participated | $200 MSeries A | |
Structure Therapeutics | Aug 2022Led | $33 MSeries B |
18 Items
18
Items
...
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 0 | 1 |
| Series B | 1 | 5 |
| Series C+ | 0 | 8 |
| Other Equity | 1 | 2 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jul '21 | 2 |
| Aug '21 | 1 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 2 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 1 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 1 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 2 |
| Apr '23 | 0 |
| May '23 | 1 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 1 |
| Mar '24 | 1 |
| Apr '24 | 1 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 1 |
| Dec '24 | 0 |
| Jan '25 | 1 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 1 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 1 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 1 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 17 |
| Manufacturing | 2 |
| Marketing & Advertising | 1 |
| Hardware & Robotics | 1 |
| Consumer & Lifestyle | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 0 |
| $25M-$50M | 1 |
| $50M-$100M | 0 |
| $100M-$250M | 14 |
| $250M-$500M | 3 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 4 of 4 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 12 |
| Europe | 4 |
| Australia | 1 |
| Canada | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Ally Bridge Group | 9 |
| Janus Henderson Investors | 8 |
| T. Rowe Price Associates | 8 |
| Omega Funds | 7 |
| Avidity Partners | 6 |
| Invus | 5 |
| RA Capital Management | 5 |
| Deep Track Capital | 4 |
| Fidelity Management & Research Company | 4 |
| SV Health Investors | 4 |
| Andera Partners | 3 |
| ARCH Venture Partners | 3 |
| Cormorant Asset Management | 3 |
| EQT Life Sciences (LSP) | 3 |
| Eventide Asset Management | 3 |
| Lilly Asia Ventures | 3 |
| Logos Capital | 3 |
| Longitude Capital | 3 |
| Pfizer Ventures | 3 |
| RTW Investments | 3 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 2 | 11% |
| Participating | 16 | 89% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 0 | 0% |
| Co-led | 2 | 100% |
Team
No team members found for this fund.